Industry

VANCOUVER, British Columbia & SEATTLE–(BUSINESS WIRE)–Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported, as required by the New York Stock Exchange Listed Company Manual Rule 303A.08 (the “NYSE Rule”), an equity inducement award to Dr. Paul Moore, Zymeworks’ new Chief Scientific Officer. In accordance with the NYSE Rule, Zymeworks approved … [Read more…]

CARLSBAD, Calif.–(BUSINESS WIRE)–Ra Medical Systems, Inc. (NYSE American: RMED) (“Ra Medical” or the “Company) announces a reduction in the exercise price of all existing warrants that were issued in the February 2022 public offering, consisting of Series A Warrants and Series B Warrants, from $0.50 per share to $0.28 per share, and entry into a … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Gastroesophageal Reflux Disease Devices Market Research Report by Product Type, Procedure Type, Device Type, Surgery Type, Route of Administration, Dosage Form, End-User, Region – Global Forecast to 2027 – Cumulative Impact of COVID-19” report has been added to ResearchAndMarkets.com’s offering. The Global Gastroesophageal Reflux Disease Devices Market size was estimated at USD 4,550.91 … [Read more…]

– Positive Opinion Based on HELIOS-A Phase 3 Study – – European Commission Decision Expected in September 2022 – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending … [Read more…]

Approval recommended for first-line treatment of advanced melanoma patients with tumor cell PD-L1 expression < 1% Recommendation based on results from the Phase 2/3 RELATIVITY-047 trial, in which the fixed-dose combination of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab more than doubled median progression-free survival compared to nivolumab monotherapy If approved, it would … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Artificial Cervical Intervertebral Disc Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Material, End User, and Geography” report has been added to ResearchAndMarkets.com’s offering. The artificial cervical intervertebral disc market size is expected to grow from US$ 1,621.66 million in 2022 to US$ 4,375.29 million by 2028; it is estimated … [Read more…]

Double-Digit Growth in Reported and Adjusted Revenue Sensient Operating at or Above its 2022 Guidance MILWAUKEE–(BUSINESS WIRE)–Sensient Technologies Corporation (NYSE: SXT) reported consolidated revenue of $371.7 million in this year’s second quarter compared to $335.8 million in last year’s second quarter. Reported operating income in the second quarter of 2022 was $55.2 million compared to … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Antimicrobial Resistance Diagnostic Markets, Strategies and Trends by Pathogen and Technology, with Executive Guides and Customization” report has been added to ResearchAndMarkets.com’s offering. Make investment decisions and valuations with confidence using the latest data and 5 year forecasts Diagnostics are leading the charge in reducing the threat posed by antimicrobial resistance. Will these … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Emerging Singlecell Technology Startups 2022” report has been added to ResearchAndMarkets.com’s offering. The global single-cell technology (SCT) market has emerged since the mid-2010s. The SCT is defined as any cell biology research tool that provides single cell resolution handling and data sets, for example, single cell (SC) picking up/dispensing, SC-sequencing, and SC-protein analysis … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “UAE Cancer Diagnostics Market, By Product (Consumable v/s Instruments), By Technology, By Application, By End User, By Region, Competition Forecast & Opportunities, 2017-2027” report has been added to ResearchAndMarkets.com’s offering. The UAE cancer diagnostics market is expected to grow at a steady rate in the forecast period. The market growth can be attributed … [Read more…]